The Health Technology Assessment (HTA) Accelerator from IQVIA lets you analyze past and current payer assessments and evidence requirements to guide clinical trial design and market access strategy across the product lifecycle.
In June 2022, most of the 29 oncology reports from five countries are expected to be published on the first, ninth and around the 22nd and 23rd.
If you want to have a demo or to request a strategic analysis by our consultants, please visit here or contact hta-accelerator@iqvia.com
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
Access clearer, more compelling support to demonstrate the value of your product.
Get insights into payer decision making and evidence requirements to accelerate market access for your drug.
